Par Expects To Launch Megestrol Suspension In August After Appellate Win
Executive Summary
Par Pharmaceutical expects to launch generic megestrol oral suspension in August, following a federal appellate court decision upholding its patent challenge to Bristol-Myers Squibb's Megace.
You may also be interested in...
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
Bristol Megace
Patent infringement complaint against Par Pharmaceutical regarding megestrol oral formulation dismissed Dec. 14 by the New York Southern District Court. Par's counterclaims for patent invalidity, unfair competition and interference remain. Par received a tentative approval in October and anticipates marketing no later than February 2002